Cas9 Stable Cell Line - MOLT-4

The MOLT-4 cell line was originally established from the peripheral blood of a patient diagnosed with T-cell acute lymphoblastic leukemia. Characterized by its suspension growth and T-lymphocyte properties, it has become a staple in hematology and immunology research. The Cas9-stable MOLT-4 cell line is a derivative engineered to constitutively express the Streptococcus pyogenes Cas9 nuclease. By integrating the Cas9 gene into the host cell genome—often through lentiviral transduction followed by rigorous antibiotic selection—this line ensures high-level, uniform nuclease expression across the entire population. This stable integration bypasses the challenges associated with transiently co-delivering large Cas9 expression vectors, which often result in low transfection efficiency and high cell mortality in lymphoid lines. Consequently, these cells provide a standardized and robust genetic background for consistent genome engineering.

In practical applications, the Cas9-stable MOLT-4 cell line serves as a high-efficiency tool for functional genomics and drug discovery. It is primarily used to facilitate rapid gene knockout or knock-in experiments through the delivery of single guide RNAs (sgRNAs) alone, significantly simplifying the CRISPR workflow. This is particularly advantageous for large-scale, pooled library screens aimed at identifying essential genes involved in leukemogenesis or mapping resistance pathways to chemotherapy. Beyond oncology, the line is extensively utilized in virology, specifically to investigate HIV-1 entry mechanisms and host dependency factors, given MOLT-4’s high sensitivity to viral infection. By reducing the experimental variability inherent in transient transfection, the line allows for more reproducible data in downstream assays such as flow cytometry, western blotting, and phenotypic characterization, making it an essential resource for modern molecular biology laboratories.